The biotherapeutics company publishes new research on the experiences of people living with the rare lung disease IPF, identifying critical gaps in diagnosis, treatment, and quality of life.
The biotechnology company will present data from its Phase 2b trial of deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis at an upcoming medical conference.
This biotechnology firm reported mixed annual results, showcasing clinical advancements and improved financials. Despite increased revenue and promising trial outcomes, operational losses and funding challenges persist, reflecting the sector's inherent risks.
The biotechnology company has announced it will publish its annual results and hold a conference call to discuss the findings.
The healthcare company has provided a regulatory update on its holdings.
The biotechnology company has appointed Peel Hunt as a joint UK corporate broker alongside UBS.
The biotechnology company confirms it is in discussions with Nordic Capital about a possible offer, but provides no further details.
The biotechnology company has appointed a seasoned financial and operational executive to its board, bolstering its leadership as it advances its pipeline.
The biotechnology company announces the vesting of restricted share units for certain directors and managers, with no significant financial details provided.
The healthcare company will present at an upcoming investor conference, providing an opportunity to share updates with the investment community.